No Data
Huatai Research Starts Hunan Fangsheng Pharmaceutical at Buy With 13.99 Yuan
Express News | Hunan Fangsheng Pharmaceutical: Xuesaitong tablets are planned to be selected for the national Chinese Patent Medicine procurement alliance's centralized bulk purchasing.
Express News | Hunan Fangsheng Pharmaceutical: Subsidiary Fangsheng Jianmeng has been recognized as a high-tech enterprise.
Hunan Fangsheng Pharmaceutical (603998.SH): Changes occurred in the partnership shares of the merger and acquisition Fund established through investments.
On December 16, Gelonghui reported that Hunan Fangsheng Pharmaceutical (603998.SH) announced that on December 13, 2024, the company received a notice from Zhuhai Hengqin Zhongke Jianchuang Investment Partnership (Limited Partnership) (referred to as "Zhongke Jianchuang"). Zhongke Jianchuang agreed to allow Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. (referred to as "Maipu Technology") to subscribe for an additional partner share of 26.49 million yuan for 30 million yuan, and the company waived its right of first refusal. This change in the partner share of Zhongke Jianchuang does not harm the company's interests, and the number of partner shares held by the company has not changed (partner shares.
Hunan Fangsheng Pharmaceutical (603998): Innovation empowers and blooms in multiple areas.
Investment highlights: hunan fangsheng pharmaceutical is a large health industry group with innovative drugs in traditional chinese medicine as its core. The company was established in 2002 and has built platforms in pharmaceutical manufacturing, the health industry, and medical services through its own development and investment mergers and acquisitions, along with its business.
Express News | Over 20 listed companies announced after hours that pharmaceuticals have been included in the new national medical insurance catalog, with multiple innovative drugs among them.
